Skip to main content
. Author manuscript; available in PMC: 2014 Jul 21.
Published in final edited form as: Nat Cell Biol. 2014 Apr 20;16(5):457–468. doi: 10.1038/ncb2953

Figure 5. Galectin-3 is essential for Integrin β3/KRAS complex.

Figure 5

(a) Confocal microscopy images show immunostaining for integrin β3 (green), KRAS (red) and DNA (TOPRO-3, blue) for PANC-1 cells expressing non-target shRNA control (shCTRL) or Galectin-3-specific shRNA (shGal-3) grown in 3D. Scale bar, 10 μm. Data are representative of three independent experiments. (b) Immunoblot analysis of KRAS immunoprecipitates from PANC-1 cells expressing non-target shRNA control (shCTRL) or Galectin-3-specific shRNA (shGal-3). Data are representative of 3 independent experiments.(c) Effect Galectin-3 knockdown on β3-mediated erlotinib resistance in FGβ3 cells. n= 3 independent experiments (3 technical replicates per experiment); mean ± SD.(d) Effect of Galectin-3 knockdown on erlotinib response measured by CellTiterGLO cell viability assay for FG, and FGβ3. Data are expressed in relative Luciferase Units (RLU). Cells were grown in 3D and treated with 1μM of erlotinib. n=3 independent experiments (2 technical replicates per experiment); mean ± SD. (e) Self-renewal capacity of PANC-1 cells expressing non-target shRNA control (shCTRL) or Galectin-3-specific shRNA (shGal-3) measured by quantifying the number of primary and secondary tumorspheres. n=3 wells per group; mean ± SD. Data are representative of 2 independent experiments. Phase contrast images of self-renewal tumorspheres of PANC-1 cells expressing non-silencing shRNA CTRL or Galectin-3 specific shRNA. Scale bar, 100 μm. P value was estimated by Student’s t-test in c,d,e.*P< 0.05, **P< 0.01, **P< 0.01 Uncropped western-blots are provided in Supplementary Figure 7 and original data for c,d,e are provided in the Statistical Source data (Supplementary Table 3).